Highlights Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Delayed Hong Kong S.E. Other stock markets 02:13:16 2024-07-04 am EDT			5-day change	1st Jan Change
1.47 ^HKD	-0.68%		-2.65%	-59.39%

Jun. 13	Jacobio Pharmaceuticals Group Co., Ltd. commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.	CI
Jun. 07	Jacobio Pharmaceuticals Group Co., Ltd.'s Equity Buyback announced on July 24, 2023, has expired.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jacobio Pharmaceuticals Group Co., Ltd. commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.	Jun. 13	CI
Jacobio Pharmaceuticals Group Co., Ltd.'s Equity Buyback announced on July 24, 2023, has expired.	Jun. 06	CI
Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector	Jun. 03	MT
Jacobio Pharmaceuticals Presents Data on Lung Cancer Treatment at US Oncology Meet; Shares Surge 12%	Jun. 03	MT
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO	Jun. 01	CI
Jacobio Pharmaceuticals Group Co., Ltd. Announces New Drug Application for Its Independently Developed Novel KRAS G12C Inhibitor Glecirasib (Jab-21822)	May. 21	CI
Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	May. 10	CI
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%	May. 06	MT
Jacobio Pharmaceuticals Group Co., Ltd. Announces Submission of New Drug Application for KRAS G12C Inhibitor Glecirasib (JAB-21822)	May. 06	CI
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint	Apr. 30	CI
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention	Apr. 09	MT
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting	Apr. 09	CI
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses	Apr. 01	MT
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300	Feb. 29	CI
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor	Feb. 18	CI
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI	Jan. 19	CI
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium	Dec. 06	CI
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo	23-10-22	CI
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Highlights

Filters